FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Ultra Seal Extra Strength Headache Relief Recall

Extra Strength Headache Relief (Acetaminophen 250 mg/aspirin 250 mg/Caffeine 65 mg) tab…

Ultra Seal Corporation · New Paltz, NY

Risk level
Class III
Reported by FDA
Aug 26, 2020
Recall ID
D-1513-2020
Check your lot numberHow we source this data

Summary

Ultra Seal recalled Extra Strength Headache Relief starting Aug 3, 2020. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-1513-2020 on Aug 26, 2020. Reason: Failed Stability Specifications: Out-of-Specification (OOS) results for the Aspirin related compound Salicylic Acid was observed. Status: Terminated.

Why it was recalled

Failed Stability Specifications: Out-of-Specification (OOS) results for the Aspirin related compound Salicylic Acid was observed.

Product description

Extra Strength Headache Relief (Acetaminophen 250 mg/aspirin 250 mg/Caffeine 65 mg) tablets, 2-tablet packets, Manufactured for: Convenience Valet Glendale Heights, IL 60139,

Lot numbers, UPCs & expiration codes

Lot #: K-8909, AK8909, Exp. Date 12/2020; AK9507, Exp. Date 03/2021; AK9072, Exp. Date 04/2021; AK9102, AK9601, AK9679, Exp. Date 05/2021; AK9145, K9145, Exp. Date 06/2021; AK9743, AK9830, Exp. Date 07/2021; AK9276, Exp. Date 09/2021; AK9391, A9392, Exp. Date 12/2021; AK9505, Exp. Date 02/2022; AK9508, AK9509 Exp. Date 04/2022

Where it was sold

Product was shipped to two distributors in IL and TX who may have further repackaged and distributed the product.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1513-2020
Classification
Class III
Status
Terminated
Recall initiated
Aug 3, 2020
FDA report date
Aug 26, 2020
Quantity
701,735 packets
Recall type
Voluntary: Firm initiated
Recalling firm
Ultra Seal Corporation

Original FDA data

Every field from FDA enforcement report D-1513-2020, exactly as published.

Show all FDA fields
City
New Paltz
State
NY
Status
Terminated
Country
United States
Event ID
86264
Address
521 Main St
Code information
Lot #: K-8909, AK8909, Exp. Date 12/2020; AK9507, Exp. Date 03/2021; AK9072, Exp. Date 04/2021; AK9102, AK9601, AK9679, Exp. Date 05/2021; AK9145, K9145, Exp. Date 06/2021; AK9743, AK9830, Exp. Date 07/2021; AK9276, Exp. Date 09/2021; AK9391, A9392, Exp. Date 12/2021; AK9505, Exp. Date 02/2022; AK9508, AK9509 Exp. Date 04/2022
Postal code
12561-1609
Report date
Aug 26, 2020
Product type
Drugs
Recall number
D-1513-2020
Classification
Class III
Recalling firm
Ultra Seal Corporation
Product quantity
701,735 packets
Termination date
Mar 16, 2021
Reason for recall
Failed Stability Specifications: Out-of-Specification (OOS) results for the Aspirin related compound Salicylic Acid was observed.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Extra Strength Headache Relief (Acetaminophen 250 mg/aspirin 250 mg/Caffeine 65 mg) tablets, 2-tablet packets, Manufactured for: Convenience Valet Glendale Heights, IL 60139,
Distribution pattern
Product was shipped to two distributors in IL and TX who may have further repackaged and distributed the product.
Recall initiation date
Aug 3, 2020
Initial firm notification
Letter
Center classification date
Aug 20, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1513-2020, published Aug 26, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls